BC Extra | Nov 20, 2019
Company News

Management tracks: Vifor, Relay, I-Mab, Yumanity, Savara and more

Vifor Pharma Ltd. (SIX:VIFN) hired Lee Heeson as president international. Heeson, who was president of worldwide markets responsible for the inflammation and immunology franchise in all ex-U.S. markets at Celgene Corp. (NASDAQ:CELG), will also join...
BC Extra | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

Roche's Gazyva clears Phase II hurdle in lupus nephritis  Gazyva obinutuzumab from Roche (SIX:ROG; OTCQX:RHHBY) met the primary endpoint in the Phase II NOBILITY trial to treat lupus nephritis. Given in combination with standard of...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Jul 27, 2018
Financial News

Savara raises $48.9M follow-on

Pulmonary disease company Savara Inc. (NASDAQ:SVRA) raised $48.9 million on July 26 through the sale of 4.3 million shares at $11.50 in a follow-on underwritten by Jefferies, Evercore, Canaccord Genuity, JMP Securities and H.C. Wainwright....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BioCentury | Jul 7, 2017
Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
BC Week In Review | Jun 9, 2017
Financial News

Savara raises $43M in follow-on

Rare respiratory disease company Savara Inc. (NASDAQ:SVRA) raised $43 million through the sale of 9 million shares at $4.75 in a follow-on underwritten by Jefferies, Canaccord Genuity and JMP Securities. The figures include the sale...
BC Week In Review | May 26, 2017
Clinical News

Savara amends Phase III IMPALA trial of Molgradex

Following guidance from FDA, Savara Inc. (NASDAQ:SVRA) amended the ongoing Phase II/III IMPALA trial evaluating Molgradex to treat autoimmune pulmonary alveolar proteinosis (PAP). Specifically, Savara increased enrollment from 51 to 90 patients. Additionally, the company...
BC Week In Review | May 3, 2017
Financial News

Savara completes $7.5M debt financing

On May 1, Savara Inc. (NASDAQ:SVRA) drew down $7.5 million of a $15 million debt facility from Silicon Valley Bank. Savara Inc. (NASDAQ:SVRA), Austin, Texas ...
Items per page:
1 - 10 of 27
BC Extra | Nov 20, 2019
Company News

Management tracks: Vifor, Relay, I-Mab, Yumanity, Savara and more

Vifor Pharma Ltd. (SIX:VIFN) hired Lee Heeson as president international. Heeson, who was president of worldwide markets responsible for the inflammation and immunology franchise in all ex-U.S. markets at Celgene Corp. (NASDAQ:CELG), will also join...
BC Extra | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

Roche's Gazyva clears Phase II hurdle in lupus nephritis  Gazyva obinutuzumab from Roche (SIX:ROG; OTCQX:RHHBY) met the primary endpoint in the Phase II NOBILITY trial to treat lupus nephritis. Given in combination with standard of...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Jul 27, 2018
Financial News

Savara raises $48.9M follow-on

Pulmonary disease company Savara Inc. (NASDAQ:SVRA) raised $48.9 million on July 26 through the sale of 4.3 million shares at $11.50 in a follow-on underwritten by Jefferies, Evercore, Canaccord Genuity, JMP Securities and H.C. Wainwright....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BioCentury | Jul 7, 2017
Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
BC Week In Review | Jun 9, 2017
Financial News

Savara raises $43M in follow-on

Rare respiratory disease company Savara Inc. (NASDAQ:SVRA) raised $43 million through the sale of 9 million shares at $4.75 in a follow-on underwritten by Jefferies, Canaccord Genuity and JMP Securities. The figures include the sale...
BC Week In Review | May 26, 2017
Clinical News

Savara amends Phase III IMPALA trial of Molgradex

Following guidance from FDA, Savara Inc. (NASDAQ:SVRA) amended the ongoing Phase II/III IMPALA trial evaluating Molgradex to treat autoimmune pulmonary alveolar proteinosis (PAP). Specifically, Savara increased enrollment from 51 to 90 patients. Additionally, the company...
BC Week In Review | May 3, 2017
Financial News

Savara completes $7.5M debt financing

On May 1, Savara Inc. (NASDAQ:SVRA) drew down $7.5 million of a $15 million debt facility from Silicon Valley Bank. Savara Inc. (NASDAQ:SVRA), Austin, Texas ...
Items per page:
1 - 10 of 27